How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.

Name

Novel Selective CYP11B1 Inhibitors - Cushing's, metabolic syndrome treatment

Organization name

PVA Saarland

Profile

Background

Steroid-11β-hydroxylase (CYP11B1) is localised in the adrenal cortex and plays a crucial role in glucocorticoid formation. Elevated cortisol levels are associated with Cushing’s syndrome or metabolic disease. As CYP11B1 catalyses the final step in cortisol biosynthesis, its inhibition with selective compounds is a promising strategy for the treatment of these diseases. There are inhibitors of cortisol biosynthesis such as Ketoconazole, Etomidate or Metyrapone in clinical use, but all of them show severe side effects due to the fact that they are unselective against other steroidogenic CYP enzymes (CYP11B2, CYP17, CYP19). A special challenge in the development of CYP11B1 inhibitors is to reach sufficient selectivity versus CYP11B2, the key enzyme in mineralocorticoid biosynthesis, as both enzymes show an enormously high identity of 93 %.

Invention

Scientists of Saarland University have recently succeeded in developing the first CYP11B1 inhibitors showing good selectivity. As starting point the highly active CYP11B1 inhibitor Etomidate has been used. Via several modifications followed by further optimizations realized at this molecule, it was possible to increase the selectivity resulting in a very weak inhibition towards CYP11B2 and no inhibition of CYP17 and CYP19. Activities of the inhibitors are also comparable to Ketoconazole and Metyrapone that are already used in clinical practice. The newly synthesized CYP11B1 inhibitors show superior selectivities to the known active agents in an outstanding manner.

For data please see the flyer.

Advantages

  • Selective effect on CYP11B1-enzymes
  • very small weak to non- inhibition towards other steroidogenic CYP-enzymes
  • Outstanding activities
  • Treatment of Cushing's syndrome
  • Treatment of metabolic syndrome

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.

 
 

latest entries